Breakthrough HIV drug sees 18 patent filings, may delay affordable generics | India News
An unusually high 18 patent applications filed in India for lenacapavir NEW DELHI: An unusually high 18 patent applications filed in India for lenacapavir, a breakthrough HIV therapy, have raised concerns that these could prolong market exclusivity, delay affordable generics, keep prices high and restrict patient access. Contesting the move, patient groups and civil society…
